Drug‑drug interactions in diabetic patients at the department of clinical pharmacology

Czech version

Authors: L. Magulová ¹; T. Foltánová ²
Authors‘ workplace: Oddelenie klinickej farmakológie Fakultnej nemocnice Nitra, Slovenská republika, vedúci pracoviska PharmDr. Lívia Magulová, Ph. D. ¹; Katedra farmakológie a toxikológie liečiv Farmaceutické fakulty UK Bratislava, Slovenská republika, prednosta prof. PharmDr. Ján Kyselovič, CSc. ²
Published in: Vnitř Lék 2009; 55(4): 403-407
Category:

Overview

Drug‑drug interactions in diabetic patients could be serious, even life threatening. Possible manifestation of hypo/hyperglycemia as a consequence of drug‑drug interactions are often wrong interpreted as a nonadherence to the diabetic diet or polymorbidity of the patient. Drug‑drug interactions are not taken into account. The risk of drug‑drug interactions is exponentially increasing with the number of taken drugs. In the group of diabetic patients is good to prevent the combinations of drugs, which can lead to drug‑drug interactions and use alternative therapy with lower potential of drug‑drug interactions. In this paper we present the possibilities of clinical pharmacist from the Department of clinical pharmacology to prevent and solve the drug‑drug interactions in diabetic patients.

Key words:
drug‑drug interactions – diabetic patients – alternative combinations

Sources

1. Baxter K. Stockley’s Drug Interactions. 7th ed. London: Pharmaceutical Press 2006: 917–958.

2. Tatro DS. Drug interaction facts. St. Louis: Wolters Kluwer Health 2008.

3. Magulová L, Božeková L, Kriška M et al. Interakcie liečiv v klinickej praxi. 2. vyd. Bratislava: SAP 2004.

4. Walker R, Edwards C. Clinical Pharmacy and Therapeutics. 2th ed. Edinburgh: Churchill Livingstone 1999.

5. Katzung BG. Základní a klinická farmakologie. 2. vyd. Praha: H&H Vyšehradská 2006: 1070–1081.

6. Ďurišová A. Interakcie liečiv u detí. Čes Slov Pediat 2005; 60: 428–432.

7. Khamaisi M, Leitersdorf E. Severe hypoglycemia from clarithromycin‑repaglinide drug interaction. Pharmacotherapy 2008; 28: 682–684.

8. Šmahelová A. Metformin a ledviny. Vnitř Lék 2008; 54: 535–540.

9. Arnold JM, Yusuf S, Young J et al. HOPE Investigators. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107: 1284–1290.

10. Magula D, Dvořák F, Ondrisová Z. Miesto klinickej biochémie v monitorovaní nežiaducich účinkov farmakoterapie. Lab diagnostika 2000; 5: 64–65.

11. Wawruch M, Fialová D, Žikavská M et al. Používanie potenciálne nevhodných liečiv pre starších pacientov v regióne Česko-Slovenska. Klin Farmakol Farm 2008; 22: 108–110.